TEST:

Next-Gen CRC Screening Test

P=N/A; Recruiting --> Active, not recruiting | N=20000 --> 196

"Epigenomics Inc...announced...The new updated version of the “Next-Gen” assay, which incorporates in-licensed technology, achieved 84% sensitivity at 90% specificity and an advanced adenoma detection rate of 20% in pre-clinical testing. Results were based on a total of 241 subjects, ranging in age from 45-to-85, excluding advanced adenomas and including 70 CRC positive samples equally distributed between early (Stages 1&2) and late (Stages 3&4) stages of the disease. The Next-Gen test is a simple, easy to use, multiomics-solution that employs both DNA methylation markers with protein targets to assess an individual patient’s risk of having colorectal cancer."

P=N/A | N=20000 | Recruiting | Sponsor: Epigenomics, Inc

"Epigenomics Inc...announced it has enrolled its first subject in a new pivotal clinical trial supporting the Company’s 'Next-Generation' blood-based diagnostic screening test for the detection of colorectal cancer (CRC)...The prospective, multi-center study titled CRC-DRAW (CRC–Detection Reliable Assessment With Blood) will enroll screening eligible participants 45 years of age and older who are at average risk for colorectal cancer."